

- [33] Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, et al. H5N1 influenza: a protean pandemic threat. *Proc Natl Acad Sci U S A* 2004;101:8156-61.
- [40] Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated Influenza Vaccines. In: Plotkin SA, A. OW, A. OP, editors. *Vaccines 5th ed.*; Saunders-Elsevier, 2008.
- [43] Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, et al. Influenza: emergence and control. *J Virol* 2004;78:8951-9.
- [44] Girard MP, Osterhaus A, Pervikov Y, Palkonyay L, Kieny MP. Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007. *Vaccine* 2008;26:2443-50.
- [45] Girard M, Palkonyay L, Kieny MP. Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials" World Health Organization, Geneva, Switzerland, 14-15 February 2008. *Vaccine* 2008.
- [52] Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. *Nat Med* 2008;14:558-64.
- [53] Influenza in the world. *Wkly Epidemiol Rec* 2004;79:385-8.
- [54] Cases of influenza A (H5N1)--Thailand, 2004. *MMWR Morb Mortal Wkly Rep* 2004;53:100-3.
- [55] Palese P. Influenza: old and new threats. *Nat Med* 2004;10:S82-7.
- [56] Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. *Jama* 2003;289:179-86.
- [57] Grijalva CG, Craig AS, Dupont WD, Bridges CB, Schrag SJ, Iwane MK, et al. Estimating influenza hospitalizations among children. *Emerg Infect Dis* 2006;12:103-9.
- [58] Musher DM. How contagious are common respiratory tract infections? *N Engl J Med* 2003;348:1256-66.
- [59] Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. *Pediatr Infect Dis J* 2004;23:189-97.
- [60] Ghendon YZ, Kaira AN, Elshina GA. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. *Epidemiol Infect* 2006;134:71-8.
- [61] Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. *PLoS Med* 2006;3:e89.
- [62] Cox NJ, Subbarao K. Influenza. *Lancet* 1999;354:1277-82.
- [63] Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. *Vaccine* 2008;26 D31-D4.
- [64] Kilbourne ED. Influenza pandemics of the 20th century. *Emerg Infect Dis* 2006;12:9-14.
- [65] Enserink M, Normile D. Infectious diseases. True numbers remain elusive in bird flu outbreak. *Science* 2005;307:1865.
- [66] <http://pandemic.influenza.com>.
- [67] Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. *J Public Health Policy* 2005;26:4-29.
- [68] Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. *J Infect Dis* 2007;195:1018-28.
- [69] Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis* 2008;198:962-70.
- [70] McCullers JA. Planning for an influenza pandemic: thinking beyond the virus. *J Infect Dis* 2008;198:945-7.
- [71] Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. *Lancet* 1998;351:472-7.
- [72] Liu J, Xiao H, Lei F, Zhu Q, Qin K, Zhang XW, et al. Highly pathogenic H5N1 influenza virus infection in migratory birds. *Science* 2005;309:1206.
- [73] Chen H, Smith GJ, Zhang SY, Qin K, Wang J, Li KS, et al. Avian flu: H5N1 virus outbreak in migratory waterfowl. *Nature* 2005;436:191-2.

- [74] Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. *J Virol* 2006;80:3495-505.
- [75] Webster RG, Govorkova EA. H5N1 influenza--continuing evolution and spread. *N Engl J Med* 2006;355:2174-7.
- [76] van den Berg T, Lambrecht B, Marche S, Steensels M, Van Borm S, Bublot M. Influenza vaccines and vaccination strategies in birds. *Comp Immunol Microbiol Infect Dis* 2008;31:121-65.
- [77] Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. *Proc Natl Acad Sci U S A* 2006;103:2845-50.
- [78] Fedson DS. Vaccine development for an imminent pandemic: why we should worry, what we must do. *Hum Vaccin* 2006;2:38-42.
- [79] Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, Van Hoeven N, et al. Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. *Proc Natl Acad Sci U S A* 2008;105:7558-63.
- [80] Bouvier NM, Palese P. The biology of influenza viruses. *Vaccine* 2008;26:D49-D53.
- [81] Reid AH, Taubenberger JK, Fanning TG. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. *Nat Rev Microbiol* 2004;2:909-14.
- [82] Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. *Nature* 2005;437:889-93.
- [83] Holmes EC, Ghedin E, Miller N, Taylor J, Bao Y, St George K, et al. Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. *PLoS Biol* 2005;3:e300.
- [84] Schweiger B, Bruns L, Meixenberger K. Reassortment between human A(H3N2) viruses is an important evolutionary mechanism. *Vaccine* 2006;24:6683-90.
- [85] Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. *Nature* 2008;453:615-9.
- [86] Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, et al. Transmission of equine influenza virus to dogs. *Science* 2005;310:482-5.
- [87] Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA. Influenza B virus in seals. *Science* 2000;288:1051-3.
- [88] Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. *Annu Rev Biochem* 1987;56:365-94.
- [89] Carr CM, Kim PS. Flu virus invasion: halfway there. *Science* 1994;266:234-6.
- [90] Colman PM, Lawrence MC. The structural biology of type I viral membrane fusion. *Nat Rev Mol Cell Biol* 2003;4:309-19.
- [91] Swalley SE, Baker BM, Calder LJ, Harrison SC, Skehel JJ, Wiley DC. Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation. *Biochemistry* 2004;43:5902-11.
- [92] Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. *Science* 2001;293:1840-2.
- [93] Gu J, Xie Z, Gao Z, Liu J, Korteweg C, Ye J, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. *Lancet* 2007;370:1137-45.
- [94] Kuiken T, Taubenberger JK. Pathology of human influenza revisited. *Vaccine* 2008;26::D59-D66.
- [95] Parrish CR, Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. *Annu Rev Microbiol* 2005;59:553-86.
- [96] van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, et al. H5N1 Virus Attachment to Lower Respiratory Tract. *Science* 2006;312:399.
- [97] Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, Pappas C, et al. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. *Science* 2007;315:655-9.

- [98] Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, Smith DF, et al. Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. *Science* 2007;317:825-8.
- [99] Wasilenko JL, Lee CW, Sarmento L, Spackman E, Kapczynski DR, Suarez DL, et al. NP, PB1, and PB2 viral genes contribute to altered replication of H5N1 avian influenza viruses in chickens. *J Virol* 2008;82:4544-53.
- [100] Li Z, Jiang Y, Jiao P, Wang A, Zhao F, Tian G, et al. The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. *J Virol* 2006;80:11115-23.
- [101] Cauthen AN, Swayne DE, Sekellick MJ, Marcus PI, Suarez DL. Amelioration of influenza virus pathogenesis in chickens attributed to the enhanced interferon-inducing capacity of a virus with a truncated NS1 gene. *J Virol* 2007;81:1838-47.
- [102] Hulse-Post DJ, Franks J, Boyd K, Salomon R, Hoffmann E, Yen HL, et al. Molecular changes in the polymerase genes (PA and PB1) associated with high pathogenicity of H5N1 influenza virus in mallard ducks. *J Virol* 2007;81:8515-24.
- [103] Jiao P, Tian G, Li Y, Deng G, Jiang Y, Liu C, et al. A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. *J Virol* 2008;82:1146-54.
- [104] Zhu Q, Yang H, Chen W, Cao W, Zhong G, Jiao P, et al. A naturally occurring deletion in its NS gene contributes to the attenuation of an H5N1 swine influenza virus in chickens. *J Virol* 2008;82:220-8.
- [105] Mizgerd JP. Acute lower respiratory tract infection. *N Engl J Med* 2008;358:716-27.
- [106] Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. *J Infect Dis* 2006;194 Suppl 2:S111-8.
- [107] Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. *N Engl J Med* 2000;342:232-9.
- [108] Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. *Jama* 2006;296:1990-7.
- [109] Bardiya N, Bae JH. Influenza vaccines: recent advances in production technologies. *Appl Microbiol Biotechnol* 2005;67:299-305.
- [110] Rose GW, Cooper CL. Fluarix, inactivated split-virus influenza vaccine. *Expert Opin Biol Ther* 2006;6:301-10.
- [111] Hovden AO, Cox RJ, Madhun A, Haaheim LR. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. *Scand J Immunol* 2005;62:342-52.
- [112] Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. *J Virol* 2008;82:4612-9.
- [113] Goodman MJ, Nordin JD, Harper P, Defor T, Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. *Pediatrics* 2006;117:e821-6.
- [114] Ohmit SE, Victor JC, Rothhoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. *N Engl J Med* 2006;355:2513-22.
- [115] Manzoli L, Schioppa F, Boccia A, Villari P. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. *Pediatr Infect Dis J* 2007;26:97-106.
- [116] Ohmit SE, Victor JC, Teich ER, Truscon RK, Rothhoff JR, Newton DW, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. *J Infect Dis* 2008;198:312-7.
- [117] Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. *J Infect Dis* 2009;199:159-67.
- [118] Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. *N Engl J Med* 2003;348:1322-32.

- [119] Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med* 2007;357:1373-81.
- [120] Jansen AG, Sanders EA, Nichol KL, van Loon AM, Hoes AW, Hak E. Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program. *Vaccine* 2008;26:5567-74.
- [121] Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. *Pediatrics* 2006;118:e579-85.
- [122] Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. *Pediatrics* 2005;115:1039-47.
- [123] McElhaney JE, Hooton JW, Hooton N, Bleackley RC. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. *Vaccine* 2005;23:3294-300.
- [124] Quentin-Millet M-J. 8th WHO IVR Global Vaccine Research Forum. Paris; 2008 June.
- [125] McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? *J Infect Dis* 2008;198:632-4.
- [126] Holland D, Booy R, Looze FD, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial. *J Infect Dis* 2008.
- [127] Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. *Pediatrics* 2007;119:1076-82.
- [128] Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic *Escherichia coli* enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. *J Virol* 2006;80:4962-70.
- [129] Glezen WP. Herd protection against influenza. *J Clin Virol* 2006;37:237-43.
- [130] Schwartz B, Hinman A, Abramson J, Strikas RA, Allred N, Uyeki T, et al. Universal influenza vaccination in the United States: are we ready? Report of a meeting. *J Infect Dis* 2006;194 Suppl 2:S147-54.
- [131] Belshe RB. Current status of live attenuated influenza virus vaccine in the US. *Virus Res* 2004;103:177-85.
- [132] Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. *Arch Pediatr Adolesc Med* 2004;158:65-73.
- [133] Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. *Pediatrics* 2006;118:2298-312.
- [134] Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. *Vaccine* 2005;23:1540-8.
- [135] Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. *N Engl J Med* 2007;356:685-96.
- [136] Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. *Pediatr Infect Dis J* 2006;25:870-9.
- [137] Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. *Pediatr Infect Dis J* 2006;25:860-9.

- [138] Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. *Pediatr Infect Dis J* 2008;27:444-52.
- [139] Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. *Pediatrics* 2007;120:e553-64.
- [140] Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. *Vaccine* 2008;26:4940-6.
- [141] Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. *Pediatr Infect Dis J* 2004;23:138-44.
- [142] Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, et al. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age. *Pediatrics* 2008;121:e568-73.
- [143] Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided by live attenuated influenza vaccine in children. *Pediatr Infect Dis J* 2008;27:744-8.
- [144] Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, et al. Live cold-adapted influenza A vaccine produced in Vero cell line. *Virus Res* 2004;103:187-93.
- [145] Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. *Clin Vaccine Immunol* 2008;15:1042-53.
- [146] Fiers W, De Filette M, Birkett A, Neiryck S, Min Jou W. A "universal" human influenza A vaccine. *Virus Res* 2004;103:173-6.
- [147] Casetti MC, Couch R, Wood J, Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. *Vaccine* 2005;23:1529-33.
- [148] De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. *Vaccine* 2006;24:6597-601.
- [149] De Filette M, Ramne A, Birkett A, Lycke N, Lowenadler B, Min Jou W, et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. *Vaccine* 2006;24:544-51.
- [150] Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B, et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. *Vaccine* 2008;26:1243-52.
- [151] Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. *PLoS ONE* 2008;3:e2257.
- [152] Marshall JD, Heeke DS, Abbate C, Yee P, Van Nest G. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. *Immunology* 2006;117:38-46.
- [153] Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. *Vaccine* 2005;23:5751-9.
- [154] Galarza JM, Latham T, Cupo A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. *Viral Immunol* 2005;18:365-72.
- [155] Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. *J Virol* 2007;81:3514-24.
- [156] Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. *Vaccine* 2007;25:3871-8.

- [157] Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. *Jama* 2007;297:1577-82.
- [158] Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. *Lancet* 2006;367:475-81.
- [159] Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. *Curr Drug Targets Infect Disord* 2003;3:263-71.
- [160] Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. *J Virol* 2007;81:150-8.
- [161] Freedman DO, Leder K. Influenza: changing approaches to prevention and treatment in travelers. *J Travel Med* 2005;12:36-44.
- [162] [http://www.who.int/vaccine\\_research/disease/influenza/flu\\_trials\\_tables/en/index.html](http://www.who.int/vaccine_research/disease/influenza/flu_trials_tables/en/index.html).
- [163] Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *N Engl J Med* 2006;354:1343-51.
- [164] Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. *Lancet* 2006;367:1657-64.
- [165] Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. *J Infect Dis* 2008;197:580-3.
- [166] Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. *Lancet Infect Dis* 2004;4:499-509.
- [167] Luke CJ, Subbarao K. Vaccines for pandemic influenza. *Emerg Infect Dis* 2006;12:66-72.
- [168] Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. *Vaccine* 2008;26:4160-7.
- [169] Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. *Lancet* 2001;357:1937-43.
- [170] Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. *J Infect Dis* 2008;197:667-75.
- [171] Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. *PLoS ONE* 2008;3:e1665.
- [172] Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. *Lancet* 2007;370:580-9.
- [173] Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgue S, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. *J Infect Dis* 2008;198:642-9.
- [174] Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. *Vaccine* 2007;25:3955-61.
- [175] Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. *Lancet* 2006;368:991-7.
- [176] Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. *Vaccine* 2006;24:5452-60.

- [177] Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. *N Engl J Med* 2008;358:2573-84.
- [178] Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, et al. Safety and immunogenicity of a pre-pandemic influenza A (H5N1) vaccine in children. *Pediatr Infect Dis J* 2008;27:1052-6.
- [179] Suguitan AL, Jr., McAuliffe J, Mills KL, Jin H, Duke G, Lu B, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. *PLoS Med* 2006;3:e360.
- [180] Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. *Vaccine* 2006;24:6859-66.
- [181] Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A, Tumpey TM, Van Hoven N, Carter VS, et al. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. *J Virol* 2007;81:11817-27.
- [182] Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. *Vaccine* 2009;27:530-41.
- [183] Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. *J Virol* 2006;80:1959-64.
- [184] Kreijtz JH, Suezter Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. *J Infect Dis* 2007;195:1598-606.
- [185] Veits J, Romer-Oberdorfer A, Helferich D, Durban M, Suezter Y, Sutter G, et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. *Vaccine* 2008;26:1688-96.
- [186] Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. *Vaccine* 2006;24:2176-85.
- [187] Wei CJ, Xu L, Kong WP, Shi W, Canis K, Stevens J, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. *J Virol* 2008;82:6200-8.